Pharma and healthcare: sector news on Tuesday 10 November 2026
Average tone +3.1 (positive) across 4 companies with relevant coverage, from 29 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| GSK | +6.3 | 13 | Coverage focused on positive cancer and HIV trial data, pipeline updates at the Guggenheim conference and growth in Specialty Medicines. |
| AstraZeneca | +5.5 | 12 | Coverage was mainly about a reported $10 billion proposal for Rhythm Pharmaceuticals and a new C4XD licensing deal, both pointing to pipeline expansion. |
| Haleon | +5.7 | 3 | Coverage centred on reported revenue growth, a new consumer health education initiative in Canada, and director confidence in a recovery. |
| Smith & Nephew | −5.0 | 1 | Coverage was thin, with the only relevant item being a piece on another wound care stock that refers to a collapsed merger involving Smith & Nephew. |
| Convatec | — | 0 |
Strongest stories in the sector
- +9.2 Positive oncology and HIV trial outcomes viewed as beneficial for investors.
- +8.3 Broker raises price target, showing analyst confidence.
- +8.3 Real-world data favours ViiV's long-acting HIV treatment over daily pills.
- +6.7 Neutral: attention on GSK over fresh oncology results and proteomics.
- +6.7 Faster late-stage programmes in respiratory and long-acting treatments.
- +6.7 Growth led by Specialty Medicines ahead of investor events.
- +6.3 Annual sales reported with solid mid-single-digit growth.
- +5.8 Analyst ratings with price forecasts well above current levels.
- +5.8 Directors' share dealings reflect confidence in a recovery.
- −5.8 Refers to a failed large merger involving the company, though focus is another stock.
- +5.0 Large proposed acquisition signals growth ambitions in rare disease area.
- +5.0 New licensing agreement adds to its development pipeline.
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.